Immunotherapy and chemotherapy for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage III non-small cell lung cancer that cannot be removed with surgery.
- You have at least one tumor that can be measured on a scan.
- Your doctor has confirmed that your overall health is good enough to possibly have surgery later.
- You have not had any prior treatment for a thymic epithelial tumor (a chest tumor near the heart).
- You do not have an active autoimmune disease that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Hear when a new Unresectable Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.